BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PharmStar Pharmaceuticals, Inc. to Pursue SEC Fully-Reporting Status


10/31/2011 8:39:15 AM

WILSON, NC--(Marketwire - October 31, 2011) -

PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR) (the "Company") announced today that it has started the process of becoming a fully-reporting company under U.S. Securities and Exchange Commission (SEC) regulations, in preparation for listing its shares on the OTC Bulletin Board (OTCBB).

Fully-reporting SEC status will allow PharmStar to pursue a listing on NASDAQ's OTC Bulletin Board, a regulated quotation service that displays real-time quotes, last-sale prices, and market depth and volume information for over-the-counter securities.

"I am committed to continuing our policy of transparency and complete disclosure, and this process is therefore mandatory for us if we are to achieve our goals," stated PharmStar CEO Howard Phykitt. "I believe that a listing on the OTCBB will enhance investor interest and confidence, lower our cost of capital, and make our stock more attractive to institutional investors. As the Company continues to progress toward this listing we will update our shareholders accordingly. As a first step, we have identified our audit firm and have begun organizing our historical corporate operations and financial results. We will then prepare SEC filings in anticipation of transitioning to fully-reporting status and application to the OTCBB early next year."

The Company completed the initial step in the process of becoming fully-reporting by retaining the accounting firm of Labrozzi & Company, P.A. The firm will immediately initiate an audit of PharmStar Pharmaceuticals, Inc. and its operations.

The Company's major milestones include completing its audit (4-6 weeks), the filing of a Form 10 (9-12 weeks) and 15c211, and the probable filing of an S1 registration. The Company's management expects the total process to take approximately 4 to 6 months.

About PharmStar Pharmaceuticals, Inc.
PharmStar Pharmaceuticals, Inc. ("PharmStar") is a U.S.-based drug development, manufacturing and marketing company and the innovator of the FDA-approved liquid pain reliever, Aquaprin™. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin, and is now ready for commercialization. Aquaprin™'s unique, multiple patent-pending formulas are designed to dissolve nearly instantly in just 1.5 ounces or more of water. This enables the product to be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset.

PharmStar initially plans to sell Aquaprin™ directly to nursing homes, outpatient and health care clinics, emergency units of hospitals nationwide, as well as retail distribution in selected local markets and third-party websites to be announced. All package engineering, product stability; shelf life testing and quality control research has been completed. PharmStar's headquarters are located in Wilson, NC.

Forward-Looking Statements Disclosure
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "will," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.


Contact:
PharmStar Pharmaceuticals, Inc.
919-794-7000
info@pharmstarinc.com
www.pharmstarinc.com

Investor Contact:
investors@pharmstarinc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES